APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pet Cancer Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pet Cancer Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025209 pages

Choose your research edition.

Industry ResearchPet Cancer Therapeutics Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Pet Cancer Therapeutics Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Pet Cancer Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pet Cancer Therapeutics Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Pet Cancer Therapeutics Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Pet Cancer Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pet Cancer Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pet Cancer Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pet Cancer Therapeutics market include Zoetis, Zenoaq, VetiVax, VetDC, Inc, Rhizen Pharmaceutical SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, Ngelheim International GmbH and Morphogenesis, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pet Cancer Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pet Cancer Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pet Cancer Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pet Cancer Therapeutics market.

Pet Cancer Therapeutics Segment by Company

Zoetis

Zenoaq

VetiVax

VetDC, Inc

Rhizen Pharmaceutical SA

Regeneus Ltd.

Oasmia Pharmaceuticals AB

Ngelheim International GmbH

Morphogenesis, Inc

Merial Inc

Karyopharm Therapeutics, Inc

ELIAS Animal Health

Elanco

Boehringer Ingelheim International GmbH

Aratana Therapeutics, Inc

AB Science

Pet Cancer Therapeutics Segment by Type

Immunotherapy

Combination Therapy

Chemotherapy

Targeted Therapy

Pet Cancer Therapeutics Segment by Application

Mammary

Squamous Cell Cancer

Lymphoma

Melanoma

Mast Cell Cancer

Others

Pet Cancer Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pet Cancer Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pet Cancer Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Pet Cancer Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pet Cancer Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pet Cancer Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Pet Cancer Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pet Cancer Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pet Cancer Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pet Cancer Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pet Cancer Therapeutics industry.

Chapter 3: Detailed analysis of Pet Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pet Cancer Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pet Cancer Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pet Cancer Therapeutics Industry Trends Table 2. Pet Cancer Therapeutics Industry Drivers Table 3. Pet Cancer Therapeutics Industry Opportunities and Challenges Table 4. Pet Cancer Therapeutics Industry Restraints Table 5. Global Pet Cancer Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pet Cancer Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Pet Cancer Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pet Cancer Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Pet Cancer Therapeutics Company, Product Type & Application Table 10. Global Pet Cancer Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pet Cancer Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Immunotherapy Table 15. Significant Companies of Combination Therapy Table 16. Significant Companies of Chemotherapy Table 17. Significant Companies of Targeted Therapy Table 18. Global Pet Cancer Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pet Cancer Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pet Cancer Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pet Cancer Therapeutics Sales Value Share by Type (2021-2026) Table 22. Global Pet Cancer Therapeutics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Mammary Table 24. Significant Companies of Squamous Cell Cancer Table 25. Significant Companies of Lymphoma Table 26. Significant Companies of Melanoma Table 27. Significant Companies of Mast Cell Cancer Table 28. Significant Companies of Others Table 29. Global Pet Cancer Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pet Cancer Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Pet Cancer Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Pet Cancer Therapeutics Sales Value Share by Application (2021-2026) Table 33. Global Pet Cancer Therapeutics Sales Value Share by Application (2027-2032) Table 34. Global Pet Cancer Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Pet Cancer Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Pet Cancer Therapeutics Sales Value Share by Region (2021-2026) Table 37. Global Pet Cancer Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Pet Cancer Therapeutics Sales Value Share by Region (2027-2032) Table 39. Global Pet Cancer Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pet Cancer Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Pet Cancer Therapeutics Sales Value Market Share by Country (2021-2026) Table 42. Global Pet Cancer Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Pet Cancer Therapeutics Sales Value Market Share by Country (2027-2032) Table 44. Zoetis Company Information Table 45. Zoetis Business Overview Table 46. Zoetis Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Zoetis Pet Cancer Therapeutics Product Portfolio Table 48. Zoetis Recent Development Table 49. Zenoaq Company Information Table 50. Zenoaq Business Overview Table 51. Zenoaq Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Zenoaq Pet Cancer Therapeutics Product Portfolio Table 53. Zenoaq Recent Development Table 54. VetiVax Company Information Table 55. VetiVax Business Overview Table 56. VetiVax Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. VetiVax Pet Cancer Therapeutics Product Portfolio Table 58. VetiVax Recent Development Table 59. VetDC, Inc Company Information Table 60. VetDC, Inc Business Overview Table 61. VetDC, Inc Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. VetDC, Inc Pet Cancer Therapeutics Product Portfolio Table 63. VetDC, Inc Recent Development Table 64. Rhizen Pharmaceutical SA Company Information Table 65. Rhizen Pharmaceutical SA Business Overview Table 66. Rhizen Pharmaceutical SA Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Rhizen Pharmaceutical SA Pet Cancer Therapeutics Product Portfolio Table 68. Rhizen Pharmaceutical SA Recent Development Table 69. Regeneus Ltd. Company Information Table 70. Regeneus Ltd. Business Overview Table 71. Regeneus Ltd. Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Regeneus Ltd. Pet Cancer Therapeutics Product Portfolio Table 73. Regeneus Ltd. Recent Development Table 74. Oasmia Pharmaceuticals AB Company Information Table 75. Oasmia Pharmaceuticals AB Business Overview Table 76. Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Product Portfolio Table 78. Oasmia Pharmaceuticals AB Recent Development Table 79. Ngelheim International GmbH Company Information Table 80. Ngelheim International GmbH Business Overview Table 81. Ngelheim International GmbH Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Ngelheim International GmbH Pet Cancer Therapeutics Product Portfolio Table 83. Ngelheim International GmbH Recent Development Table 84. Morphogenesis, Inc Company Information Table 85. Morphogenesis, Inc Business Overview Table 86. Morphogenesis, Inc Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Morphogenesis, Inc Pet Cancer Therapeutics Product Portfolio Table 88. Morphogenesis, Inc Recent Development Table 89. Merial Inc Company Information Table 90. Merial Inc Business Overview Table 91. Merial Inc Pet Cancer Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Merial Inc Pet Cancer Therapeutics Product Portfolio Table 93. Merial Inc Recent Development Table 94. Karyopharm Therapeutics, Inc Company Information Table 95. Karyopharm Therapeutics, Inc Business Overview Table 96. Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio Table 98. Karyopharm Therapeutics, Inc Recent Development Table 99. ELIAS Animal Health Company Information Table 100. ELIAS Animal Health Business Overview Table 101. ELIAS Animal Health Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. ELIAS Animal Health Pet Cancer Therapeutics Product Portfolio Table 103. ELIAS Animal Health Recent Development Table 104. Elanco Company Information Table 105. Elanco Business Overview Table 106. Elanco Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Elanco Pet Cancer Therapeutics Product Portfolio Table 108. Elanco Recent Development Table 109. Boehringer Ingelheim International GmbH Company Information Table 110. Boehringer Ingelheim International GmbH Business Overview Table 111. Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Product Portfolio Table 113. Boehringer Ingelheim International GmbH Recent Development Table 114. Aratana Therapeutics, Inc Company Information Table 115. Aratana Therapeutics, Inc Business Overview Table 116. Aratana Therapeutics, Inc Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Aratana Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio Table 118. Aratana Therapeutics, Inc Recent Development Table 119. AB Science Company Information Table 120. AB Science Business Overview Table 121. AB Science Pet Cancer Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. AB Science Pet Cancer Therapeutics Product Portfolio Table 123. AB Science Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Pet Cancer Therapeutics Product Image Figure 2. Global Pet Cancer Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pet Cancer Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Pet Cancer Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Immunotherapy Image Figure 8. Combination Therapy Image Figure 9. Chemotherapy Image Figure 10. Targeted Therapy Image Figure 11. Global Pet Cancer Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pet Cancer Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pet Cancer Therapeutics Sales Value Share by Type (2021-2032) Figure 14. Mammary Image Figure 15. Squamous Cell Cancer Image Figure 16. Lymphoma Image Figure 17. Melanoma Image Figure 18. Mast Cell Cancer Image Figure 19. Others Image Figure 20. Global Pet Cancer Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Pet Cancer Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Pet Cancer Therapeutics Sales Value Share by Application (2021-2032) Figure 23. Global Pet Cancer Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Pet Cancer Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Pet Cancer Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. North America Pet Cancer Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Pet Cancer Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Pet Cancer Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Pet Cancer Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Pet Cancer Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Pet Cancer Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 32. South America Pet Cancer Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Pet Cancer Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Pet Cancer Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapy
  • Combination Therapy
  • Chemotherapy
  • Targeted Therapy
Applications
  • Mammary
  • Squamous Cell Cancer
  • Lymphoma
  • Melanoma
  • Mast Cell Cancer
  • Others
Companies covered
  • Zoetis
  • Zenoaq
  • VetiVax
  • VetDC, Inc
  • Rhizen Pharmaceutical SA
  • Regeneus Ltd.
  • Oasmia Pharmaceuticals AB
  • Ngelheim International GmbH
  • Morphogenesis, Inc
  • Merial Inc
  • Karyopharm Therapeutics, Inc
  • ELIAS Animal Health
  • Elanco
  • Boehringer Ingelheim International GmbH
  • Aratana Therapeutics, Inc
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pet Cancer Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pet Cancer Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pet Cancer Therapeutics Market Dynamics
  1. 2.1 Pet Cancer Therapeutics Industry Trends
  2. 2.2 Pet Cancer Therapeutics Industry Drivers
  3. 2.3 Pet Cancer Therapeutics Industry Opportunities and Challenges
  4. 2.4 Pet Cancer Therapeutics Industry Restraints
3 Pet Cancer Therapeutics Market by Company
  1. 3.1 Global Pet Cancer Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Pet Cancer Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Pet Cancer Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Pet Cancer Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Pet Cancer Therapeutics Company Product Type and Application
  6. 3.6 Global Pet Cancer Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pet Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pet Cancer Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pet Cancer Therapeutics Market by Type
  1. 4.1 Pet Cancer Therapeutics Type Introduction
  2. 4.1.1 Immunotherapy
  3. 4.1.2 Combination Therapy
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Targeted Therapy
  6. 4.2 Global Pet Cancer Therapeutics Sales Value by Type
  7. 4.2.1 Global Pet Cancer Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pet Cancer Therapeutics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pet Cancer Therapeutics Sales Value Share by Type (2021-2032)
5 Pet Cancer Therapeutics Market by Application
  1. 5.1 Pet Cancer Therapeutics Application Introduction
  2. 5.1.1 Mammary
  3. 5.1.2 Squamous Cell Cancer
  4. 5.1.3 Lymphoma
  5. 5.1.4 Melanoma
  6. 5.1.5 Mast Cell Cancer
  7. 5.1.6 Others
  8. 5.2 Global Pet Cancer Therapeutics Sales Value by Application
  9. 5.2.1 Global Pet Cancer Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Pet Cancer Therapeutics Sales Value by Application (2021-2032)
  11. 5.2.3 Global Pet Cancer Therapeutics Sales Value Share by Application (2021-2032)
6 Pet Cancer Therapeutics Regional Value Analysis
  1. 6.1 Global Pet Cancer Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pet Cancer Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pet Cancer Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pet Cancer Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pet Cancer Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Pet Cancer Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pet Cancer Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Pet Cancer Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pet Cancer Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pet Cancer Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pet Cancer Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Pet Cancer Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pet Cancer Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pet Cancer Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Pet Cancer Therapeutics Country-level Value Analysis
  1. 7.1 Global Pet Cancer Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pet Cancer Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pet Cancer Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pet Cancer Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pet Cancer Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pet Cancer Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pet Cancer Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zoetis
  2. 8.1.1 Zoetis Company Information
  3. 8.1.2 Zoetis Business Overview
  4. 8.1.3 Zoetis Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zoetis Pet Cancer Therapeutics Product Portfolio
  6. 8.1.5 Zoetis Recent Developments
  7. 8.2 Zenoaq
  8. 8.2.1 Zenoaq Company Information
  9. 8.2.2 Zenoaq Business Overview
  10. 8.2.3 Zenoaq Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zenoaq Pet Cancer Therapeutics Product Portfolio
  12. 8.2.5 Zenoaq Recent Developments
  13. 8.3 VetiVax
  14. 8.3.1 VetiVax Company Information
  15. 8.3.2 VetiVax Business Overview
  16. 8.3.3 VetiVax Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 VetiVax Pet Cancer Therapeutics Product Portfolio
  18. 8.3.5 VetiVax Recent Developments
  19. 8.4 VetDC, Inc
  20. 8.4.1 VetDC, Inc Company Information
  21. 8.4.2 VetDC, Inc Business Overview
  22. 8.4.3 VetDC, Inc Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 VetDC, Inc Pet Cancer Therapeutics Product Portfolio
  24. 8.4.5 VetDC, Inc Recent Developments
  25. 8.5 Rhizen Pharmaceutical SA
  26. 8.5.1 Rhizen Pharmaceutical SA Company Information
  27. 8.5.2 Rhizen Pharmaceutical SA Business Overview
  28. 8.5.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Product Portfolio
  30. 8.5.5 Rhizen Pharmaceutical SA Recent Developments
  31. 8.6 Regeneus Ltd.
  32. 8.6.1 Regeneus Ltd. Company Information
  33. 8.6.2 Regeneus Ltd. Business Overview
  34. 8.6.3 Regeneus Ltd. Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneus Ltd. Pet Cancer Therapeutics Product Portfolio
  36. 8.6.5 Regeneus Ltd. Recent Developments
  37. 8.7 Oasmia Pharmaceuticals AB
  38. 8.7.1 Oasmia Pharmaceuticals AB Company Information
  39. 8.7.2 Oasmia Pharmaceuticals AB Business Overview
  40. 8.7.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Product Portfolio
  42. 8.7.5 Oasmia Pharmaceuticals AB Recent Developments
  43. 8.8 Ngelheim International GmbH
  44. 8.8.1 Ngelheim International GmbH Company Information
  45. 8.8.2 Ngelheim International GmbH Business Overview
  46. 8.8.3 Ngelheim International GmbH Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ngelheim International GmbH Pet Cancer Therapeutics Product Portfolio
  48. 8.8.5 Ngelheim International GmbH Recent Developments
  49. 8.9 Morphogenesis, Inc
  50. 8.9.1 Morphogenesis, Inc Company Information
  51. 8.9.2 Morphogenesis, Inc Business Overview
  52. 8.9.3 Morphogenesis, Inc Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Morphogenesis, Inc Pet Cancer Therapeutics Product Portfolio
  54. 8.9.5 Morphogenesis, Inc Recent Developments
  55. 8.10 Merial Inc
  56. 8.10.1 Merial Inc Company Information
  57. 8.10.2 Merial Inc Business Overview
  58. 8.10.3 Merial Inc Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merial Inc Pet Cancer Therapeutics Product Portfolio
  60. 8.10.5 Merial Inc Recent Developments
  61. 8.11 Karyopharm Therapeutics, Inc
  62. 8.11.1 Karyopharm Therapeutics, Inc Company Information
  63. 8.11.2 Karyopharm Therapeutics, Inc Business Overview
  64. 8.11.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
  66. 8.11.5 Karyopharm Therapeutics, Inc Recent Developments
  67. 8.12 ELIAS Animal Health
  68. 8.12.1 ELIAS Animal Health Company Information
  69. 8.12.2 ELIAS Animal Health Business Overview
  70. 8.12.3 ELIAS Animal Health Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 ELIAS Animal Health Pet Cancer Therapeutics Product Portfolio
  72. 8.12.5 ELIAS Animal Health Recent Developments
  73. 8.13 Elanco
  74. 8.13.1 Elanco Company Information
  75. 8.13.2 Elanco Business Overview
  76. 8.13.3 Elanco Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Elanco Pet Cancer Therapeutics Product Portfolio
  78. 8.13.5 Elanco Recent Developments
  79. 8.14 Boehringer Ingelheim International GmbH
  80. 8.14.1 Boehringer Ingelheim International GmbH Company Information
  81. 8.14.2 Boehringer Ingelheim International GmbH Business Overview
  82. 8.14.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Product Portfolio
  84. 8.14.5 Boehringer Ingelheim International GmbH Recent Developments
  85. 8.15 Aratana Therapeutics, Inc
  86. 8.15.1 Aratana Therapeutics, Inc Company Information
  87. 8.15.2 Aratana Therapeutics, Inc Business Overview
  88. 8.15.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aratana Therapeutics, Inc Pet Cancer Therapeutics Product Portfolio
  90. 8.15.5 Aratana Therapeutics, Inc Recent Developments
  91. 8.16 AB Science
  92. 8.16.1 AB Science Company Information
  93. 8.16.2 AB Science Business Overview
  94. 8.16.3 AB Science Pet Cancer Therapeutics Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AB Science Pet Cancer Therapeutics Product Portfolio
  96. 8.16.5 AB Science Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst